|
KR20100016170A
|
|
Yeast expression systems
|
|
WO2008012062A1
|
|
Antigenic proteoliposomes and method of manufacture
|
|
EP1961821A1
|
|
Erythropoietin fusion protein
|
|
CA2583332A1
|
|
Liposomal composition comprising an active ingredient for relaxing smooth muscle production and therapeutically use of said composition
|
|
US2008113015A1
|
|
Superloaded Liposomes for Drug Delivery
|
|
AU2003270099A1
|
|
Generation of recombinant influenza virus using baculovirus delivery vector
|
|
CA2473163A1
|
|
Anti-idiotypic antibody inducing hiv-1 neutralizing antibodies
|
|
WO03046162A2
|
|
Process for the production of polypeptides in mammalian cell cultures
|
|
US7595049B2
|
|
IGG1 monoclonal antibody with anti-HIV neutralizing activity
|
|
AU2356002A
|
|
Live vaccine and method of manufacture
|
|
AU5035201A
|
|
Recombinant influenza a viruses
|
|
EP1627920A1
|
|
Method for the manufacture of recombinant trypsin
|
|
US7351549B2
|
|
Method for the manufacture of recombinant trypsin
|
|
AU4054001A
|
|
Method for the manufacture of recombinant trypsin
|
|
AU3020401A
|
|
Tumor and senescence marker
|
|
AU2368601A
|
|
Bioactive oligopeptides
|
|
EP1203614A1
|
|
Process and apparatus for preparing lipid vesicles
|
|
US6268484B1
|
|
HIV-vaccines
|
|
CA2204493A1
|
|
Application of superoxide dismutase in liposomes
|
|
BR9510575A
|
|
Monoclonal antibodies against hiv-1 vaccines prepared with them
|
